Spots Global Cancer Trial Database for lapatinib ditosylate
Every month we try and update this database with for lapatinib ditosylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | NCT00688194 | Breast Cancer | anastrozole exemestane fulvestrant lapatinib ditos... letrozole placebo | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors | NCT00389922 | Unspecified Adu... | lapatinib ditos... vinorelbine dit... comparative gen... cytogenetic ana... gene expression... mutation analys... polymerase chai... polymorphism an... proteomic profi... reverse transcr... immunohistochem... laboratory biom... lapatinib ditos... Vinorelbine dit... | 18 Years - | University of California, Davis | |
| GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu | NCT00085020 | Breast Cancer | trastuzumab lapatinib ditos... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | NCT00331630 | Breast Cancer | lapatinib ditos... paclitaxel albu... | 18 Years - | Northwestern University | |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | NCT00107536 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | NCT00095667 | Recurrent Prost... Stage IV Prosta... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer | NCT00424164 | Breast Cancer | lapatinib ditos... tamoxifen citra... pharmacological... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer | NCT00379509 | Breast Cancer | lapatinib ditos... TdT-mediated dU... gene expression... microarray anal... immunohistochem... biopsy radiation thera... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | NCT00667251 | Breast Cancer | trastuzumab docetaxel lapatinib ditos... paclitaxel | 18 Years - | Novartis | |
| Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | NCT00316875 | Breast Cancer | lapatinib ditos... Doxil | 18 Years - | Northwestern University | |
| Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 | NCT00544804 | Breast Cancer Metastatic Canc... | lapatinib ditos... gene expression... diagnostic labo... | 18 Years - | University of California, San Francisco | |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | NCT01622868 | HER2-Positive B... Invasive Breast... Metastatic Mali... Recurrent Breas... Stage IV Breast... | Laboratory Biom... Lapatinib Ditos... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | NCT00662636 | Unspecified Adu... | dasatinib lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | Mayo Clinic | |
| Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | NCT00113373 | Primary Periton... Recurrent Ovari... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | NCT00103194 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | NCT00684983 | HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | NCT00498953 | Head and Neck C... | carboplatin cisplatin docetaxel fluorouracil lapatinib ditos... cytogenetic ana... fluorescence in... in situ hybridi... polymerase chai... reverse transcr... immunohistochem... laboratory biom... conventional su... neoadjuvant the... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | NCT00103324 | Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage III Gastr... Stage IV Gastri... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | NCT00662636 | Unspecified Adu... | dasatinib lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | Mayo Clinic | |
| Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | NCT00769470 | Breast Cancer | trastuzumab carboplatin docetaxel lapatinib ditos... | 18 Years - 70 Years | Translational Oncology Research International | |
| Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00114283 | Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | NCT01947023 | Metastatic Thyr... Unresectable Th... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | NCT00103194 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | NCT00098605 | Central Nervous... HER2-positive B... Male Breast Can... Recurrent Breas... Stage IV Breast... Tumors Metastat... | lapatinib ditos... laboratory biom... quality-of-life... questionnaire a... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00099060 | Brain and Centr... | lapatinib ditos... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 | NCT00544804 | Breast Cancer Metastatic Canc... | lapatinib ditos... gene expression... diagnostic labo... | 18 Years - | University of California, San Francisco | |
| Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | NCT01123473 | Adenocarcinoma ... Gastric Cancer | capecitabine cisplatin epirubicin hydr... fluorouracil lapatinib ditos... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | NCT01947023 | Metastatic Thyr... Unresectable Th... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | NCT00095940 | Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | lapatinib ditos... therapeutic con... laboratory biom... pharmacological... positron emissi... magnetic resona... | - 21 Years | National Cancer Institute (NCI) | |
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen | NCT00118157 | Estrogen Recept... Male Breast Car... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Laboratory Biom... Lapatinib Ditos... Tamoxifen Citra... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | NCT00436566 | Breast Cancer Cardiac Toxicit... | trastuzumab cyclophosphamid... doxorubicin hyd... lapatinib ditos... paclitaxel gene expression... reverse transcr... fluorophotometr... laboratory biom... mass spectromet... adjuvant therap... quality-of-life... | 18 Years - 120 Years | Mayo Clinic | |
| Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | NCT00095667 | Recurrent Prost... Stage IV Prosta... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer | NCT00623064 | Bladder Cancer Transitional Ce... | cisplatin gemcitabine hyd... lapatinib ditos... pharmacological... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT00096447 | Recurrent Endom... | lapatinib ditos... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | NCT00098631 | Metastatic Squa... Recurrent Metas... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Untreated Metas... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | NCT01245205 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Unspecified Adu... | Akt inhibitor M... lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | NCT00820872 | Breast Cancer | trastuzumab carboplatin docetaxel lapatinib ditos... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | NCT01688609 | HER2-positive B... Stage II Breast... Stage IIIA Brea... | lapatinib ditos... paclitaxel trastuzumab therapeutic con... pharmacological... laboratory biom... | 20 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | NCT00095940 | Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | lapatinib ditos... therapeutic con... laboratory biom... pharmacological... positron emissi... magnetic resona... | - 21 Years | National Cancer Institute (NCI) | |
| Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | NCT00684983 | HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | NCT01245205 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Unspecified Adu... | Akt inhibitor M... lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | NCT00103324 | Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage III Gastr... Stage IV Gastri... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | NCT00107536 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer | NCT01557764 | Breast Neoplasm... | lapatinib ditos... trastuzumab | 18 Years - | Washington University School of Medicine | |
| Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 | NCT00753207 | Breast Cancer | epirubicin hydr... lapatinib ditos... biomarker analy... immunohistochem... liquid chromato... mass spectromet... | 18 Years - 120 Years | Cancer Trials Ireland | |
| Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | NCT00316875 | Breast Cancer | lapatinib ditos... Doxil | 18 Years - | Northwestern University | |
| Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors | NCT00389922 | Unspecified Adu... | lapatinib ditos... vinorelbine dit... comparative gen... cytogenetic ana... gene expression... mutation analys... polymerase chai... polymorphism an... proteomic profi... reverse transcr... immunohistochem... laboratory biom... lapatinib ditos... Vinorelbine dit... | 18 Years - | University of California, Davis | |
| Lapatinib Resistance in Patients With Breast Cancer | NCT00898573 | Breast Cancer | lapatinib ditos... fluorescence in... gene expression... mutation analys... polymerase chai... reverse transcr... cell sorting immunohistochem... laboratory biom... | - | Case Comprehensive Cancer Center | |
| Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | NCT00316875 | Breast Cancer | lapatinib ditos... Doxil | 18 Years - | Northwestern University | |
| Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00246753 | Prostate Cancer | lapatinib ditos... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 | NCT00544804 | Breast Cancer Metastatic Canc... | lapatinib ditos... gene expression... diagnostic labo... | 18 Years - | University of California, San Francisco | |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | NCT01783756 | Central Nervous... HER2-positive B... Male Breast Can... Recurrent Breas... Stage IV Breast... | lapatinib ditos... everolimus capecitabine laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Chemotherapeutic Agents in Brain/Breast | NCT00795678 | Breast Cancer Metastatic Canc... | capecitabine cyclophosphamid... doxorubicin hyd... gemcitabine hyd... lapatinib ditos... paclitaxel vinorelbine dit... Trastuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer | NCT00962312 | Pancreatic Canc... | capecitabine lapatinib ditos... | 18 Years - | Cancer Trials Ireland | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | NCT00482391 | Breast Cancer | trastuzumab cyclophosphamid... doxorubicin hyd... lapatinib ditos... paclitaxel laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer | NCT01868503 | Male Breast Can... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | lapatinib ditos... radiation thera... laboratory biom... | 18 Years - | Stanford University | |
| Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | NCT00769470 | Breast Cancer | trastuzumab carboplatin docetaxel lapatinib ditos... | 18 Years - 70 Years | Translational Oncology Research International | |
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer | NCT01104571 | Breast Cancer | trastuzumab lapatinib ditos... laboratory biom... adjuvant therap... neoadjuvant the... therapeutic con... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00246753 | Prostate Cancer | lapatinib ditos... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | NCT01118975 | Breast Cancer Neoplasm Metast... | Vorinostat Lapatinib | 18 Years - | University of Maryland, Baltimore | |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | NCT00098605 | Central Nervous... HER2-positive B... Male Breast Can... Recurrent Breas... Stage IV Breast... Tumors Metastat... | lapatinib ditos... laboratory biom... quality-of-life... questionnaire a... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | NCT00770809 | Male Breast Car... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Laboratory Biom... Lapatinib Ditos... Paclitaxel Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer | NCT01868503 | Male Breast Can... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | lapatinib ditos... radiation thera... laboratory biom... | 18 Years - | Stanford University | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
